Downtown10 had a great comment on the recent seeking-alpha article imo on short term price movement. I will add to his, how money comes into the company until they hit revenue will also play a big factor.
https://seekingalpha.com/article/4314742-cyto...-year-2020
https://seekingalpha.com/article/4314742-cyto...-year-2020
Quote:Mukticat, I commend your tenacity in attempting to find areas of uncertainty to provoke fear in the shareholders of CYDY. However, even if everything you point out are valid items of concern, with all due respect, they are nothing but noise.
What is going to move the stock price in the next 3 months is:
If the BLA is filed in Jan, the SP will rise modestly, if it is delayed beyond, the SP will drop significantly.
I doubt an FDA decision can be gotten this quarter, but an approval would cause a dramatic rise in the SP, and a CRL would crush the SP.
If an agreement is signed to partner in NASH (or possibly cancer) the SP will rise dramatically, with no agreement the SP might drift lower over time.
If the results of further cancer patients match the first 2, the SP will rise dramatically, if further results fail to confirm the results of the first 2 patients, the SP will drop significantly.
If there are positive developments with Prep from Dr. Sascha, Thai Red Cross, or the US Army the SP could rise significantly.
The questions you raise regarding the financial dealings/health of both CYDY and Vyera (some backward looking, some speculative, some irrelevant IMO), are small potatoes and simply not all that important when compared to the above-noted items which will determine where the CYDY SP goes in the next quarter or so
3
